Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie fazy II u dorosłych i młodych dorosłych pacjentów z DSRCT (ISG-TULIPS)

2 listopada 2026 zaktualizowane przez: Italian Sarcoma Group

Badanie fazy II z zastosowaniem lurbinektedyny i irynotekanu u dorosłych i młodych dorosłych pacjentów z zaawansowanym desmoplastycznym guzem okrągłokomórkowym (DSRCT)

Patients participating in this study have DSRCT that has spread locally or to other parts of the body and can no longer be surgically removed without causing significant harm.

Treatment will continue until the tumor progresses further, severe side effects occur, or either patient or investigator decision.

In addition, patients may participate in an optional biological study. The study will analyze the tumor's genes and the molecules related to them. By studying genes and their products, the investigators can better understand the behavior of the tumor and how the body responds to therapies.

Przegląd badań

Status

Rekrutacyjny

Szczegółowy opis

This is an Italian and Spanish multicentric, prospective, phase II single-arm, open-label, investigator-initiated clinical study that will be conducted within the Italian Sarcoma Group (ISG) and the Spanish Sarcoma Groups (GEIS), aiming at exploring the activity of lurbinectedinin combination with irinotecan, until progression or unacceptable toxicity, in a population of =/>15 years old patients with histologically and molecularly confirmed (EWSR1-WT1 translocation positive), advanced (locally advanced or metastatic) DSRCT, from 2nd to 4th line, following progression to anthracycline-based chemotherapy.

The primary end-point of the study will be the overall response rate (ORR) by RECIST v1.1 in the study population. Secondary end-points will be PFS, DoR, OS, safety and changes in QoL.

Patients will be evaluated for the primary end-point if have completed at least one cycle of lurbinectedin and irinotecan and have at least one post-baseline radiologic disease assessment. Patients with documented early progression disease (PD) or who die due to PD before the first scheduled tumor assessment will also be included in the analysis.

Patients will be followed for follow up visits every 6 months for 2 years.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

20

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

Lokalizacje studiów

      • Barcelona, Hiszpania, 08035
        • Jeszcze nie rekrutacja
        • Vall d'Hebron University Hospital
        • Kontakt:
        • Główny śledczy:
          • Claudia Valverde
      • Madrid, Hiszpania, 28040
        • Rekrutacyjny
        • Hospital Universitario Fundación Jiménez Díaz
        • Kontakt:
        • Główny śledczy:
          • Nadia Hindi
      • Madrid, Hiszpania, 28040
        • Jeszcze nie rekrutacja
        • Hospital Clinico Universitario San Carlos
        • Główny śledczy:
          • Gloria Marquina
        • Kontakt:
      • Murcia, Hiszpania, 30120
        • Jeszcze nie rekrutacja
        • Virgen of Arrixaca University Clinical Hospital
        • Główny śledczy:
          • Jose Luis Alonso
        • Kontakt:
          • Jose Luis Alonso, MD
      • Seville, Hiszpania, 41013
        • Jeszcze nie rekrutacja
        • Hospital Univ. Virgen del Rocío
        • Kontakt:
          • Irene Carrasco Garcìa, MD
        • Główny śledczy:
          • Irene Carrasco Garcìa
      • Zaragoza, Hiszpania, 50009
        • Jeszcze nie rekrutacja
        • Hospital Univ. Miguel Servet
        • Kontakt:
          • Javier Martinez, MD
        • Główny śledczy:
          • Javier Martinez
      • Milan, Włochy, 20133
      • Padova, Włochy, 35128
        • Rekrutacyjny
        • IOV Istituto Oncologico Veneto IRCCS
        • Główny śledczy:
          • Antonella Brunello
        • Kontakt:
      • Prato, Włochy, 59100
      • Roma, Włochy, 00128
        • Rekrutacyjny
        • Fondazione Policlinico Universitario Campus Bio-Medico
        • Główny śledczy:
          • Alessandro Mazzocca
        • Kontakt:
    • Torino
      • Candiolo, Torino, Włochy, 10060
        • Rekrutacyjny
        • Fondazione del Piemonte per l'Oncologia IRCCS
        • Kontakt:
        • Główny śledczy:
          • Sandra Aliberti

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

15 lat i starsze (Dziecko, Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. Histological centrally confirmed diagnosis of DSRCT with the documented presence of EWSR1-WT1 translocation.

  2. Age ≥ 15 years.

  3. Locally advanced (i.e. radical surgical resection of local disease unfeasible or surgery declined by the patient or surgery deemed to become less demolitive and / or easier after cytoreduction) and/or metastatic disease.

  4. Measurable disease by RECIST v1.1.

  5. Clinical or objective disease progression after the last administration of the last standard therapy, or have stopped standard therapy due to intolerability within 6 months from enrollment.

  6. At least one prior chemotherapy based on anthracycline (considering chemotherapy administered for primary tumour) and no more than 3 prior chemotherapy lines.

  7. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2.

  8. Adequate bone marrow, renal, hepatic, and metabolic function (assessed ≤ 7 days before inclusion in the trial), defined as the following:

    1. platelet count ≥ 100 × 109/L, hemoglobin ≥ 9.0 g/dL, white blood cells ≥ 3.0 × 109/L and absolute neutrophil count (ANC) ≥ 2.0 × 109/L,
    2. aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × the upper limit of normal (ULN), even in the presence of liver metastases,
    3. total bilirubin ≤ 1.5 × ULN or direct bilirubin ≤ ULN,
    4. International Normalized Ratio (INR) < 1.5 (except if patient is on oral anticoagulation therapy),
    5. calculated creatinine clearance (CrCL) ≥ 30 mL/minute (using Cockcroft-Gault formula),
    6. creatine phosphokinase (CPK) ≤ 2.5 × ULN,
    7. albumin ≥ 3.0 g/dL.
  9. Cardiac ejection fraction ≥50% as measured by echocardiogram.

  10. Recovery to grade ≤ 1 or to baseline from any adverse event (AE) derived from previous treatment (excluding alopecia and/or cutaneous toxicity and/or fatigue grade ≤ 2).

  11. No history of arterial and/or venous thromboembolic event within the previous 12 months.

  12. Females of childbearing potential must have a negative pregnancy test (preferable by serum or, if serum test unavailable, urine beta-HCG) within 7 days before treatment start.

  13. Post-menopausal women must be amenorrhoeic for at least 12 months to be considered of non-childbearing potential.

  14. Male and female patients of reproductive potential must agree to employ a highly effective method of birth control (Acceptable methods of contraception are described in Appendix 5) throughout the study and thereafter, at the end of study treatment, and for at least 7 months from the patient's last lurbinectedin administration in female patients of childbearing potential and for at least 4 months in men in fertile age after the last lurbinectedin administration.

  15. The patient or legal representative must be able to read and understand the informed consent form (ICF) and must have been willing to give written informed consent and any locally required authorisation before any study-specific procedures, including screening evaluations, sampling, and analyses.

Exclusion Criteria:

  1. Prior treatment with lurbinectedin or trabectedin, Ecubectedin (PM 14) or PM54.
  2. Known hypersensitivity to irinotecan or lurbinectedin or any of their components of the drugs products (excipients).
  3. Other primary malignancy with <5 years clinically assessed disease free interval, except basal cell skin cancer, cervical carcinoma in situ or other neoplasm judged to entail a low risk of relapse.
  4. History or presence of unstable angina, myocardial infarction, or clinically significant valvular heart disease within 12 months of the study.
  5. Grade III/IV cardiac problems as defined by the New York Heart Association Criteria (i.e. congestive heart failure, myocardial infarction within 12 months of study).
  6. Symptomatic arrhythmia or any uncontrolled arrhythmia requiring ongoing treatment within 12 months of study.
  7. Myopathy or any clinical situation that causes significant and persistent elevation of CPK (> 2.5 × ULN in two different determinations performed one week apart).
  8. Severe and/or uncontrolled medical disease (i.e. uncontrolled diabetes, chronic renal disease, or active uncontrolled infection).
  9. Known active brain metastasis.
  10. Known chronic liver disease (i.e. chronic active hepatitis and cirrhosis).
  11. Diagnosis of human deficiency virus (HIV), hepatitis C virus (HCV) infection or active hepatitis B (to be excluded during the screening period).
  12. Any past or present chronic inflammatory colon and/or liver disease, past intestinal obstruction, pseudo or sub-occlusion or paralysis.
  13. Evident symptomatic pulmonary fibrosis or interstitial pneumonitis, pleural or cardiac effusion rapidly increasing and/or necessitating prompt local treatment within seven days.
  14. Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the patient's participation in this study.
  15. Known active COVID-19 disease (this includes positive test for SARS-CoV-2 in nasopharyngeal/oropharyngeal swabs or nasal swabs by PCR).
  16. Prior bone marrow and/or stem cell transplantation, and allogenic transplant.
  17. Last dose of systemic cytotoxic therapy or investigational therapy within 21 days from enrollment.
  18. Prior treatment with any form of radiation therapy within 14 days from enrollment.
  19. Major surgery within 3 weeks prior to study entry and minor surgery within 1 week prior to study entry.
  20. Use of strong inducers of CYP3A activity within two weeks prior to the first infusion of lurbinectedin (Appendix 6).
  21. Expected limitation of the patient's ability to comply with the treatment or follow-up protocol.
  22. Subjects who have current active hepatic or biliary disease (with exception of patients with asymptomatic gallstones, liver metastasis or stable chronic liver disease per Investigator assessment).
  23. Subjects who have known Gilbert's syndrome.
  24. Patient has received a live or liver attenuated vaccines within 30 days before the first dose of study intervention. Killed vaccines are allowed.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Lurbinectedine and Irinotecan

lurbinectedin in combination with intravenous irinotecan administered until progression or unacceptable toxicity, in a population of =/>15 years old patients with histologically and molecularly confirmed (EWSR1-WT1 translocation positive), advanced (locally advanced or metastatic) DSRCT, from 2nd to 4th line, following progression to anthracycline-based chemotherapy.

Lurbinectedin and Irinotecan

Lurbinectedin and Irinotecan

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Overall tumour Response Rate (ORR), according to RECIST v 1.1
Ramy czasowe: Week 6, week 12, week 18, week 30, week 42, week 54, week 66, week 78, week 90, week 102 and until progression

Overall tumour Response Rate (ORR), according to RECIST v 1.1

Week 6, week 12, week 18, week 30, week 42, week 54, week 66, week 78, week 90, week 102 and until progression

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Overall Survival (OS)
Ramy czasowe: From date of study therapy start until the date of death from any cause, assessed up to 60 months

Overall Survival (OS)

From date of study therapy start until the date of death from any cause, assessed up to 60 months
Progression Free Survival (PFS)
Ramy czasowe: From date of study therapy start until first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

Progression Free Survival (PFS)

From date of study therapy start until first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
Duration of Response (DoR)
Ramy czasowe: From date of study therapy start until first documented assessment without progression or date of death from any cause, whichever came first, assessed up to 60 months

Duration of Response (DoR)

From date of study therapy start until first documented assessment without progression or date of death from any cause, whichever came first, assessed up to 60 months
Adverse events and Serious adverse event (according to CTC-AE v.5)
Ramy czasowe: After initiation of study treatments(s), all adverse events will be reported until 30 days after the final dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurs first.

Adverse events and Serious adverse event (according to CTC-AE v.5)

After initiation of study treatments(s), all adverse events will be reported until 30 days after the final dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurs first.
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Ramy czasowe: Screening, cycle1 day1 (each cycle is 21 days), cycle2 day1, End Of Treatment visit (performed 30 days after the last study drug administration), at follow-up visits performed at months 6, 12, 18 and 24 after the last study drug administration

The EORTC QLQ-C30 is a validated 30-item questionnaire assessing health-related quality of life in cancer patients. Scores are linearly transformed to a 0 to 100 scale.

For the Global Health Status/Quality of Life and functional scales (physical, role, emotional, cognitive, and social functioning), higher scores indicate better quality of life or functioning.

For the symptom scales and single-item symptom measures, higher scores indicate greater symptom severity (worse outcome).

Screening, cycle1 day1 (each cycle is 21 days), cycle2 day1, End Of Treatment visit (performed 30 days after the last study drug administration), at follow-up visits performed at months 6, 12, 18 and 24 after the last study drug administration
Brief Inventory Pain questionnaire
Ramy czasowe: Screening, cycle1 day1 (each cycle is 21 days), cycle2 day1, End Of Treatment visit (performed 30 days after the last study drug administration), at follow-up visits performed at months 6, 12, 18 and 24 after the last study drug administration

Brief Inventory Pain questionnaire

Screening, cycle1 day1 (each cycle is 21 days), cycle2 day1, End Of Treatment visit (performed 30 days after the last study drug administration), at follow-up visits performed at months 6, 12, 18 and 24 after the last study drug administration

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Silvia Stacchiotti, MD, Findazione IRCCS Istituto Nazionale Tumori Milano

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

21 listopada 2025

Zakończenie podstawowe (Szacowany)

1 października 2030

Ukończenie studiów (Szacowany)

1 października 2030

Daty rejestracji na studia

Pierwszy przesłany

17 listopada 2025

Pierwszy przesłany, który spełnia kryteria kontroli jakości

2 stycznia 2026

Pierwszy wysłany (Rzeczywisty)

9 stycznia 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

3 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

2 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj